Bristol Myers Squibb's Opdivo, Yervoy Show Positive Phase 3 Results for Additional Application
Bristol Myers Squibb's Opdivo, Yervoy Show Positive Phase 3 Results for Additional Application
DJ Bristol Myers Squibb's Opdivo, Yervoy Show Positive Phase 3 Results for Additional Application
By Matt Grossman
Bristol Myers Squibb Co. said Thursday that a Phase 3 trial testing the use of its Opdivo and Yervoy medications to treat unresectable advanced or metastatic esophageal squamous cell carcinoma showed positive results.
The trial tested the efficacy of two treatments: Opdivo plus chemotherapy, and Opdivo plus Yervoy.
Opdivo plus chemotherapy met its primary and secondary endpoints of providing a benefit both to patients whose tumors express PD-L1, and in the all-randomized population. The combination also met its primary endpoint of progression-free survival by blinded independent central review in patients whose tumors express PD-L1.
Opdivo plus Yervoy also demonstrated improvement in overall survival in patients whose tumors express PD-L1 and in the all-randomized population. It didn't meet the other primary endpoint of progression-free survival by BICR in patients whose tumors express PD-L1.
The drugs' safety profiles were consistent with prior research, the company said.
Dr. Ian Waxman, Bristol Myers Squibb's development lead for gastrointestinal cancers, said the results could lead to new treatment options for patients with esophageal cancer.
Write to Matt Grossman at matt.grossman@wsj.com
(END) Dow Jones Newswires
April 08, 2021 07:28 ET (11:28 GMT)
Copyright (c) 2021 Dow Jones & Company, Inc.
DJ Bristol Myers Squibb's Opdivo, Yervoy Show Positive Phase 3 Results for Additional Application
DJ百时美施贵宝(Bristol Myers Squibb)的Opdivo，Yervoy展示了额外应用的积极第三阶段结果
By Matt Grossman
马特·格罗斯曼(Matt Grossman)著
Bristol Myers Squibb Co. said Thursday that a Phase 3 trial testing the use of its Opdivo and Yervoy medications to treat unresectable advanced or metastatic esophageal squamous cell carcinoma showed positive results.
百时美施贵宝公司(Bristol Myers Squibb Co.)周四说，一项测试其Opdivo和Yerway药物治疗无法切除的晚期或转移性食管鳞癌的3期试验结果呈阳性。
The trial tested the efficacy of two treatments: Opdivo plus chemotherapy, and Opdivo plus Yervoy.
这项试验测试了两种治疗方法的疗效：Opdivo加化疗，和Opdivo加伊尔沃伊。
Opdivo plus chemotherapy met its primary and secondary endpoints of providing a benefit both to patients whose tumors express PD-L1, and in the all-randomized population. The combination also met its primary endpoint of progression-free survival by blinded independent central review in patients whose tumors express PD-L1.
Opdivo加化疗达到了它的主要和次要终点，既为肿瘤表达PD-L1的患者提供了好处，也为所有随机人群提供了好处。通过对肿瘤表达PD-L1的患者进行盲目的独立中心回顾，联合治疗也达到了无进展生存期的主要终点。
Opdivo plus Yervoy also demonstrated improvement in overall survival in patients whose tumors express PD-L1 and in the all-randomized population. It didn't meet the other primary endpoint of progression-free survival by BICR in patients whose tumors express PD-L1.
在肿瘤表达PD-L1的患者和所有随机人群中，Opdivo Plus Yervoy也显示出总体存活率的改善。在肿瘤表达PD-L1的患者中，BICR没有达到无进展生存期的另一个主要终点。
The drugs' safety profiles were consistent with prior research, the company said.
该公司表示，这些药物的安全性概况与之前的研究一致。
Dr. Ian Waxman, Bristol Myers Squibb's development lead for gastrointestinal cancers, said the results could lead to new treatment options for patients with esophageal cancer.
百时美施贵宝(Bristol Myers Squibb)胃肠道癌症开发负责人伊恩·韦克斯曼(Ian Waxman)博士表示，这一结果可能会为食道癌患者带来新的治疗选择。
Write to Matt Grossman at matt.grossman@wsj.com
写信给马特·格罗斯曼(Matt Grossman)，电子邮件：matt.grossman@wsj.com
(END) Dow Jones Newswires
(完)道琼通讯社
April 08, 2021 07:28 ET (11:28 GMT)
2021年4月8日07：28美国东部时间(格林尼治标准时间11：28)
Copyright (c) 2021 Dow Jones & Company, Inc.
版权所有(C)2021年道琼斯公司
译文内容由第三方软件翻译。
风险及免责提示
- 分享到weixin
- 分享到qq
- 分享到facebook
- 分享到twitter
- 分享到微博
- 粘贴板
使用浏览器的分享功能，分享给你的好友吧